Immunic's Participation in Evercore ISI Healthcare Conference to Share Insights on Innovative Therapies
Immunic, Inc. recently announced its upcoming participation in the 8th Annual Evercore ISI Healthcare Conference slated for December 2-4, 2025, in Coral Gables, Florida. On December 4, at 9:35 AM ET, the company’s CEO, Daniel Vitt, Ph.D., will engage in an insightful fireside chat discussing the future of innovative therapies in treating neurological and gastrointestinal diseases.
This conference offers a prime opportunity for Immunic to discuss its pioneering work in developing novel oral therapies, particularly focusing on its flagship drug candidate, vidofludimus calcium (IMU-838). This innovative therapy is currently in Phase 3 clinical trials for relapsing multiple sclerosis, and top-line data is expected to be announced by the end of 2026.
The event not only symbolizes a chance for Immunic to reinforce its corporate story but also serves as a platform to connect with investors who are keenly interested in the future of biotechnology. Alongside Dr. Vitt, Jason Tardio, the President and COO, will also be available for one-on-one meetings with interested investors throughout the conference. Those wishing to schedule a meeting are encouraged to reach out to their Evercore ISI representative, as well as to Jessica Breu, Immunic's Vice President for Investor Relations.
Immunic’s dedication to addressing unmet medical needs in the field of neurology and gastrointestinal health is underscored by the therapeutic promise of its lead candidate, vidofludimus calcium. This drug acts as a nuclear receptor related to 1 (Nurr1) activator, providing neuroprotective effects while also exhibiting anti-inflammatory and anti-viral properties by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). Its effectiveness has already been demonstrated in previous Phase 2 trials involving patients with both relapsing-remitting and progressive forms of multiple sclerosis.
Additionally, other candidates such as IMU-856 are being developed to restore intestinal barrier functions, potentially beneficial for numerous gastrointestinal disorders including celiac disease and inflammatory bowel disease. The advancement of IMU-381, currently in preclinical testing, represents another leap in Immunic’s strategy targeting gastrointestinal diseases specifically.
Investors and interested parties will be able to view the webcast of Dr. Vitt's discussion in the 'Events and Presentations' section on the Immunic website, ensuring that key insights on cutting-edge therapies are accessible for those unable to attend the conference in person.
The biotechnology industry is marked by rapid advancements and shifting landscapes, making participation in such conferences crucial. Immunic's proactive involvement illustrates its commitment to fostering investor relations and demonstrating its potential in reshaping therapeutic approaches for neurological and gastrointestinal diseases.
Overall, as Immunic steps onto this platform, it highlights a commitment not only to its developmental candidates but also to sustained dialogue with the investment community. As they move forward, all eyes will be on the promising outcomes from their clinical trials and future disclosures regarding their evolving pipeline. For more detailed information on Immunic and its innovative therapies, please visit their official website at www.imux.com.
This conference offers a prime opportunity for Immunic to discuss its pioneering work in developing novel oral therapies, particularly focusing on its flagship drug candidate, vidofludimus calcium (IMU-838). This innovative therapy is currently in Phase 3 clinical trials for relapsing multiple sclerosis, and top-line data is expected to be announced by the end of 2026.
The event not only symbolizes a chance for Immunic to reinforce its corporate story but also serves as a platform to connect with investors who are keenly interested in the future of biotechnology. Alongside Dr. Vitt, Jason Tardio, the President and COO, will also be available for one-on-one meetings with interested investors throughout the conference. Those wishing to schedule a meeting are encouraged to reach out to their Evercore ISI representative, as well as to Jessica Breu, Immunic's Vice President for Investor Relations.
Immunic’s dedication to addressing unmet medical needs in the field of neurology and gastrointestinal health is underscored by the therapeutic promise of its lead candidate, vidofludimus calcium. This drug acts as a nuclear receptor related to 1 (Nurr1) activator, providing neuroprotective effects while also exhibiting anti-inflammatory and anti-viral properties by inhibiting the enzyme dihydroorotate dehydrogenase (DHODH). Its effectiveness has already been demonstrated in previous Phase 2 trials involving patients with both relapsing-remitting and progressive forms of multiple sclerosis.
Additionally, other candidates such as IMU-856 are being developed to restore intestinal barrier functions, potentially beneficial for numerous gastrointestinal disorders including celiac disease and inflammatory bowel disease. The advancement of IMU-381, currently in preclinical testing, represents another leap in Immunic’s strategy targeting gastrointestinal diseases specifically.
Investors and interested parties will be able to view the webcast of Dr. Vitt's discussion in the 'Events and Presentations' section on the Immunic website, ensuring that key insights on cutting-edge therapies are accessible for those unable to attend the conference in person.
The biotechnology industry is marked by rapid advancements and shifting landscapes, making participation in such conferences crucial. Immunic's proactive involvement illustrates its commitment to fostering investor relations and demonstrating its potential in reshaping therapeutic approaches for neurological and gastrointestinal diseases.
Overall, as Immunic steps onto this platform, it highlights a commitment not only to its developmental candidates but also to sustained dialogue with the investment community. As they move forward, all eyes will be on the promising outcomes from their clinical trials and future disclosures regarding their evolving pipeline. For more detailed information on Immunic and its innovative therapies, please visit their official website at www.imux.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.